KAC98801
Colorimetric
Plasma, Serum
Quantitative
156.25 - 10,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
AN 100226,BG00002,CAS: 189261-10-7
A comparison of JC virus assay performance provided with originator and biosimilar natalizumab., PMID:40515643
Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?, PMID:40515642
Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing., PMID:40515640
'Should natalizumab be used despite JC virus positivity? Yes'., PMID:40515591
Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study., PMID:40505538
What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary., PMID:40485316
De-escalation of disease modifying therapies: A retrospective, observational single center study., PMID:40480031
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation., PMID:40472290
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement., PMID:40460616
Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry., PMID:40455371
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284
Real-world evidence from Türkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study., PMID:40449191
Should natalizumab be used despite JC virus positivity? No., PMID:40443199
Optimizing treatment for pediatric multiple sclerosis., PMID:40443188
Should natalizumab be used despite JC virus positivity?-Commentary., PMID:40443181
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab., PMID:40442571
Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study., PMID:40423827
Risk of stroke under disease modifying therapies for multiple sclerosis: a systematic review., PMID:40416416
Natalizumab-induced autoimmune liver injury., PMID:40414422
Natalizumab-induced autoimmune liver injury., PMID:40398815
Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis., PMID:40397308
Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study., PMID:40397068
Interventions promoting remyelination in multiple sclerosis: a systematic review of clinical trials., PMID:40393003
Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Analysis., PMID:40387571
Pediatric Multiple Sclerosis: A Systematic Exploration of Effectiveness in Current and Emerging Therapeutics., PMID:40381455
Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab., PMID:40345115
Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis., PMID:40332701
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates., PMID:40303316
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study., PMID:40296363
Recrudescence of Natalizumab-Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review., PMID:40292235
Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report., PMID:40278334
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells., PMID:40277931
Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis., PMID:40254626
Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy., PMID:40236791
Generics, Biosimilars and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists., PMID:40231751
Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy., PMID:40220724
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy., PMID:40220155
Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study., PMID:40208417
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk., PMID:40197186
Acta neurologica belgica regarding the manuscript entitled 'Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis'., PMID:40186744
Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems., PMID:40186719
Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report., PMID:40175973
Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019-2023)., PMID:40169334
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis., PMID:40163140
Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)., PMID:40156444
No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies., PMID:40144903
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis., PMID:40132877
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
